Modified immunodeficiency virus particles

• US 7,407,663 B2
• Filed: 06/20/2003
• Issued: 08/05/2008
• Est. Priority Date: 06/29/2000
• Status: Expired due to Fees

• Current Assignee: Eli Lilly and Company, Lipid Sciences, Inc.
• Original Assignee: Lipid Sciences, Inc.
• Inventors: Maltais, Jo-Ann B., Cham, Bill E.
• Primary Examiner(s): CHEN, STACY BROWN
• Application Number:
  US10/601,656
• Publication Number:
  US 20040170649A1
• Time in Patent Office: 1,873 Days
• Field of Search: 424/184.1, 424/204.1
• US Class Current: 424/208.1
• CPC Class Codes: A61K 2039/5252 inactivated (killed)
• CPC Class Codes: A61K 2039/55566 Emulsions, e.g. Freund's adjuvant, MF59
• CPC Class Codes: A61K 2039/57 characterised by the type of response, e.g. Th1, Th2
• CPC Class Codes: A61K 39/12 Viral antigens
• CPC Class Codes: A61K 39/29 Hepatitis virus
• CPC Class Codes: A61K 39/292 Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
• CPC Class Codes: A61L 2/0011 using physical methods
• CPC Class Codes: A61L 2/0088 Liquid substances
• CPC Class Codes: A61M 1/3486 Biological, chemical treatment, e.g. chemical precipitation; treatment by absorbents
• CPC Class Codes: A61P 1/16 for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• CPC Class Codes: A61P 31/00 Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• CPC Class Codes: A61P 31/04 Antibacterial agents
• CPC Class Codes: A61P 31/10 Antimycotics
• CPC Class Codes: A61P 31/12 Antivirals
• CPC Class Codes: A61P 31/14 for RNA viruses
• CPC Class Codes: A61P 31/18 for HIV
• CPC Class Codes: A61P 33/02 Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61P 7/08 Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock artificial tears A61P27/04
• CPC Class Codes: C12N 2730/10134 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
• CPC Class Codes: C12N 2730/10163 : by chemical treatment
• CPC Class Codes: C12N 2770/24334 : Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
• CPC Class Codes: C12N 2770/24363 : by chemical treatment
• CPC Class Codes: C12N 7/00 : Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00

Abstract

The present invention relates to a method for reducing the occurrence and severity of infectious diseases, especially infectious diseases in which lipid-containing infectious organisms are found in biological fluids, such as blood. The present invention employs solvents useful for extracting lipids from the lipid-containing infectious organism, thereby reducing the infectivity of the infectious organism. The present invention uses optimal solvent systems such that the lipid envelope around the viral particle is dissolved while the viral particle remains intact, resulting in a modified viral particle. The present invention also provides an autologous vaccine composition, comprising a lipid-containing infectious organism, treated with solvents to reduce the lipid content of the infectious organism, combined with a pharmaceutically acceptable carrier. The vaccine composition is administered to an animal or a human to provide protection against the lipid-containing infectious organism. The present invention further provides a simple, inexpensive and easy to use kit for delipidating fluids and for delipidation of lipid-containing organisms in a fluid.

Claims

1. A modified viral particle comprising at least a partially delipidated viral particle, wherein the partially delipidated viral particle is immunodeficiency virus and the partially delipidated viral particle:

initiates a positive immune response in an animal or human;

comprises at least one exposed epitope not usually presented to an immune system of the animal or the human by a non-delipidated viral particle; and

wherein the partially delipidated viral particle is obtained by a process consisting essentially of treating a lipid-containing viral particle with an organic solvent that is not a detergent or a surfactant.

2. The modified viral particle of claim 1, wherein the immunodeficiency virus is SIV or FIV.

3. The modified viral particle of claim 1, wherein the immunodeficiency virus is HIV.

4. The modified viral particle of claim 3, wherein the HIV is HIV-1 or HIV-2.

5. The modified viral particle of claim 1, wherein the at least one exposed epitope is a gag, p6 gag, gp66, gp41, p27, or env epitope.

6. The modified viral particle of claim 1, wherein the modified viral particle has a lower lipid content in a viral envelope as compared to the non-delipidated particle.

7. The modified viral particle of claim 1, wherein one or more protein on, in, or near the surface of the partially delipidated viral particle is conformationally changed as compared to one or more proteins on, in, or near the surface of the non-delipidated viral particle.

8. The modified viral particle of claim 1, wherein an antigenic core of the modified viral particle remains intact as compared to the non-delipidated viral particle.

9. The modified viral particle of claim 2, wherein the immunodeficiency virus is SIV and the modified viral particle retains over 90% of major protein constituents compared to the non-delipidated viral particle.

10. The modified viral particle of claim 9, wherein the major protein constituents of the modified viral particle comprise gag or env proteins.

11. The modified viral particle of claim 1, wherein the modified viral particle retains at least one immunoreactive protein.

12. The modified viral particle of claim 11, wherein the at least one immunoreactive protein is selected from the group consisting of p24, gp41 and gp120.

13. The modified viral particle of claim 12, wherein the modified viral particle comprises at least one exposed patient specific antigen that was not exposed in the non-delipidated viral particle.

14. The modified viral particle of claim 1, wherein the treating of a lipid-containing viral particle with an organic solvent that is not a detergent or a surfactant comprises:

contacting the lipid-containing viral particle in a fluid with a solvent consisting essentially of the organic solvent that is not the detergent or the surfactant and is capable of extracting lipid from the lipid-containing viral particle;

mixing the fluid and the organic solvent for a time sufficient to extract lipid from the lipid-containing viral particle;

permitting organic and aqueous phases to separate; and

,

collecting the aqueous phase containing the modified viral particle with reduced lipid content wherein the modified viral particle with reduced lipid content is capable of provoking a positive immune response when administered to the animal or the human.

15. The modified viral particle of claim 14, wherein the treating of a lipid-containing viral particle with an organic solvent that is not a detergent or a surfactant further comprises:

contacting the aqueous phase with a de-emulsifying agent capable of removing the organic solvent; and

,

separating the de-emulsifying agent and the removed organic solvent from the contacted aqueous phase.

16. The modified viral particle of claim 14, wherein the organic solvent is an alcohol, an ether, an amine, a hydrocarbon, an ester, or a combination thereof.

17. The modified viral particle of claim 16, wherein the ether is C4 to C8 ether and the alcohol is a C1 to C8 alcohol.

18. The modified viral particle of claim 15, wherein the de-emulsifying agent is an ether.

19. The modified viral particle of claim 1, further comprising a pharmaceutically acceptable carrier.

20. The modified viral particle of claim 1, wherein the at least one exposed epitope is an envelope protein epitope.

21. The modified viral particle of claim 1, wherein the modified viral particle has a lower lipid content in a viral envelope than the lipid content in an envelope of the non-delipidated viral particle.

22. The modified viral particle of claim 1, wherein the partially delipidated viral particle has an infectivity reduced by no more than 2.5 log units as compared to the non-delipidated viral particle.

23. A modified viral particle comprising at least a partially delipidated viral particle, wherein the partially delipidated viral particle is immunodeficiency virus and the partially delipidated viral particle:

initiates a positive immune response in an animal or a human;

comprises at least one exposed epitope not usually presented to an immune system of the animal or the human by a non-delipidated viral particle, wherein the modified viral particle comprises at least one immunoreactive protein selected from a group consisting of p24, gp41 and gp120; and

is obtained by a process consisting essentially of treating a lipid-containing viral particle with an organic solvent that is not a detergent or a surfactant.

24. A modified viral particle comprising at least a partially delipidated viral particle, wherein the partially delipidated viral particle is immunodeficiency virus and the partially delipidated viral particle:

initiates a positive immune response in an animal or a human;

comprises an envelope, wherein the envelope comprises no extrinsic detergent or surfactant molecules; and

,

comprises at least one exposed epitope not usually presented to an immune system of the animal or the human by a non-delipidated viral particle, wherein the modified viral particle is SIV and retains over 90% of major protein constituents compared to the non-delipidated viral particle and the major protein constituents of the modified viral particle comprise gag or env proteins;

wherein the partially delipidated viral particle is obtained by a process consisting essentially of treating a lipid-containing viral particle with an organic solvent that is not a detergent or a surfactant.